Application Segment Analysis: Infant Formula (Largest Segment) vs Dietary Supplements (Fastest-Growing Segment)

Infant formula held the largest position in the human milk oligosaccharides (HMO) market in 2026, accounting for a 86.17% share, reflecting the growing integration of HMOs into infant nutrition formulations designed to more closely replicate important functional characteristics of human milk. HMOs are valued for their role in supporting the development of a healthy gut microbiome and contributing to immune-related functions, making them increasingly important ingredients in advanced infant nutrition products. Their incorporation into formula allows manufacturers to enhance the nutritional and functional profile of products intended for infants who are not exclusively breastfed. Increasing scientific understanding of the relationship between early-life nutrition, gut health, and immune development is strengthening interest in HMO-enriched formulations. Continued innovation in infant nutrition and greater availability of structurally diverse HMO ingredients are further supporting the segment's substantial market presence.

Dietary supplements is the fastest-growing application segment, driven by increasing consumer awareness of the relationship between gut microbiota, immune function, and overall health. HMOs are gaining attention beyond infant nutrition as research continues to explore their potential applications in products intended for broader populations. Growing interest in microbiome-focused nutrition is encouraging the development of supplements incorporating specialized HMO ingredients to support digestive and immune health. Improvements in production technologies are also helping expand the availability of HMO ingredients for applications beyond traditional infant formula. As consumers increasingly seek targeted nutritional products and scientifically supported ingredients for gut health, dietary supplements are emerging as an important area of expansion for HMO applications.

Type Segment Analysis: 2'FL (Largest Segment) vs DFL (Fastest-Growing Segment)

2'FL represented the largest type segment in the human milk oligosaccharides (HMO) market in 2026, with a 47.28% share, supported by its established importance in HMO-based nutrition and its close association with naturally occurring human milk oligosaccharide profiles. Its functional relevance in supporting beneficial microbial activity and contributing to infant gut and immune development has made 2'FL an important ingredient for advanced nutritional formulations. Growing adoption of HMO-fortified infant products is strengthening demand for well-established HMO structures with recognized nutritional significance. Improvements in microbial and biotechnological production methods are also facilitating the commercial availability of 2'FL at greater scale and supporting its integration into modern nutrition products. These factors collectively reinforce its leading position within the HMO type landscape.

DFL is the fastest-growing type segment, reflecting increasing interest in expanding the range of HMO structures available for specialized nutritional applications. The development of diverse HMO formulations is enabling manufacturers to explore combinations that can address different aspects of gut microbiome support and nutritional functionality. Advances in biotechnological production are improving the ability to produce specific HMO structures with greater consistency, creating opportunities for broader commercial utilization. Growing research into the distinct functional properties of individual HMOs is also encouraging product developers to move beyond a limited set of established ingredients. As HMO applications expand across infant nutrition and emerging dietary health products, demand for differentiated HMO types such as DFL is gaining momentum.